Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics

from The EIC Scaling Club Podcast on European Deep Tech · host EIC Scaling Club

In this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.

Episode metadata supplied by the publisher feed · Published Jan 29, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics

0:00 12:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The EIC Scaling Club Podcast on European Deep Tech?

This episode is 12 minutes long.

When was this The EIC Scaling Club Podcast on European Deep Tech episode published?

This episode was published on January 29, 2025.

Can I download this The EIC Scaling Club Podcast on European Deep Tech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!